M Moia - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M Moia

Showing results (41-50 of 51) with videos related to

Pageof 6

Sort By:

Thrombosis and Haemostasis|May 1, 1997

Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study GroupF Schiele, F Lindgaerde, H Eriksson, et al.

Thrombosis and Haemostasis|January 10, 1998

Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy)G Palareti, C Manotti, A DAngelo, et al.

Journal of Thrombosis and Haemostasis : JTH|July 26, 2012

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent resultsV Pengo, L Crippa, A Falanga, et al.

Journal of Thrombosis and Haemostasis : JTH|August 13, 2003

Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulationM R Taliani, G Agnelli, P Prandoni, et al.

Lupus|August 2, 2003

Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxisP L Meroni, M Moia, R H W M Derksen, et al.

Blood|November 26, 1999

The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort studyB J Sanson, P Simioni, D Tormene, et al.

The American Journal of Medicine|May 1, 1996

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian RegistryG Finazzi, V Brancaccio, M Moia, et al.

Journal of Thrombosis and Haemostasis : JTH|June 12, 2009

The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre studyS Jowett, S Bryan, L Poller, et al.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 26, 2003

Prevention of venous thrombosis with elastic stockings during long-haul flights: the LONFLIT 5 JAP studyG Belcaro, M R Cesarone, A N Nicolaides, et al.

Journal of Thrombosis and Haemostasis : JTH|November 3, 2010

Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studiesW Saber, T Moua, E C Williams, et al.

Pageof 6

Search research articles

Showing results (41-50 of 51) with videos related to

Sort By:

Pageof 6

Thrombosis and Haemostasis|May 1, 1997

Thrombosis and Haemostasis|January 10, 1998

Journal of Thrombosis and Haemostasis : JTH|July 26, 2012

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent resultsV Pengo, L Crippa, A Falanga, et al.

Journal of Thrombosis and Haemostasis : JTH|August 13, 2003

Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulationM R Taliani, G Agnelli, P Prandoni, et al.

Lupus|August 2, 2003

Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxisP L Meroni, M Moia, R H W M Derksen, et al.

Blood|November 26, 1999

The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort studyB J Sanson, P Simioni, D Tormene, et al.

The American Journal of Medicine|May 1, 1996

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian RegistryG Finazzi, V Brancaccio, M Moia, et al.

Journal of Thrombosis and Haemostasis : JTH|June 12, 2009

The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre studyS Jowett, S Bryan, L Poller, et al.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 26, 2003

Prevention of venous thrombosis with elastic stockings during long-haul flights: the LONFLIT 5 JAP studyG Belcaro, M R Cesarone, A N Nicolaides, et al.

Journal of Thrombosis and Haemostasis : JTH|November 3, 2010

Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studiesW Saber, T Moua, E C Williams, et al.

Pageof 6